Source: Annual Congress 2011 - Role of the biomarkers in airway diseases

Abstract

Background: Lipid mediators (LMs, such as prostaglandins and leukotrienes) have been extensively studied for their role in both the onset and resolution of inflammation in airway diseases. We report here the development of a state-of-the-art quantitative lipidomics-based method for the analysis of LMs using Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS).
Aims: Develop a sensitive LC-MS/MS platform to quantify LMs from multiple biological matrices including urine, bronchoalveolar lavage fluid (BALF) and sputum. The method should encompass LMs from arachidonic (AA), linoleic (LA), dihomo-γ-linolenic (DGHLA), α-linolenic (α-LA), eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acid pathways.
Methods: Pooled BALF from patients with sarcoidosis (n=5) was extracted by Solid Phase Extraction and analytes were quantified by LC-MS/MS (Acquity-Xevo, Waters). The method assess 87 LMs in combination with 16 deuterated internal standards.
Results: In BALF from sarcoidosis patients, 29 LMs from six fatty acid were detected; but only 8 LMs from each of the AA and LA pathways were quantifiable. The fatty acid origin and biosynthesis pathway of the 29 LMs is shown in Fig.1.

Conclusions: LC-MS/MS methods for LM quantification are applicable for exploring the etiology and pathology of respiratory diseases as exemplified with BALF from sarcoidosis patients. These methods will be useful in examining inflammatory processes.

Rating:

Share or cite this content

Citations should be made in the following way:
D. Balgoma, S. L. Lundström, A. Eklund, J. Grunewald, C. E. Wheelock (Stockholm, Sweden). Development of mass spectrometry approaches to quantifying lipid mediators in airway disease. Eur Respir J 2011; 38: Suppl. 55, 4794

Member's Comments

No comment yet.

Related content which might interest you: Contribution of mass spectrometry (SELDI-TOF-MS) to the analysis of low molecular weight proteins in acute and chronic asthma models Source: Annual Congress 2008 - Novel mechanisms in the pathogenesis of pulmonary inflammation Year: 2008 Improved biomarkers of cystic fibrosis lung disease in bronchoalveolar lavage fluid identified using SELDI-TOF mass spectrometry Source: Eur Respir J 2004; 24: Suppl. 48, 213s Year: 2004 In depth mass spectrometry based proteomic approach to explore the effect of curcumin in IL17A mediated alveolar barrier injury Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Differential ion mobility spectrometry for detection of metabolites in exhaled breath in airway diseases Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009 Mass spectrometry proteomic biomarkers identify acute COPD exacerbations Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Discrimination of protein and peptide composition of exhaled breath condensate in patients with pulmonary disease by mass spectrometry Source: Annual Congress 2011 - Role of the biomarkers in airway diseases Year: 2011 Metabolic profiling detects biomarkers of protein degradation in COPD patients Source: Eur Respir J 2012; 40: 345-355 Year: 2012 Desmosine as a biomarker of elastin degradation in COPD: current status and future directions Source: Eur Respir J 2008; 32: 1146-1157 Year: 2008 The application of mass spectrometry to the analysis and characterization of protein and peptide composition in exhaled breath condensate of pneumo-oncological diseased persons Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 LSC - 2018 - Characterization of decellularized COPD lung matrices using mass spectrometry proteomics Source: International Congress 2018 – COPD: novel pathological mechanisms in the airway epithelium Year: 2018 Ion mobility spectrometry in medical diagnostics: proof of inflammation markers in different parliamentary groups of the exhaled breath Source: Annual Congress 2008 - Assessment of the respiratory system Year: 2008 Determination of volatile organic compounds in exhaled breath of patients with chronic obstructive pulmonary disease by gas chromatography mass spectrometry Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 Expiratory gas analysis using mass spectrometry in chronic obstructive pulmonary disease Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Detection of infectious agents in the airways by ion mobility spectrometry in exhaled breath Source: Annual Congress 2010 - Mechanisms of respiratory infections Year: 2010 Metabolomic fingerprinting of serum samples based on direct infusion mass spectrometry for lung cancer diagnosis Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 A liquid chromatography MS/MS metabolomics study of COPD patients Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Diagnostic accuracy of SELDI-TOF-MS (surface enhanced laser desabsorbtion ionization time of flight mass spectrometry) method in early diagnosis of lung cancer Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011 The value of rapid speciation of nontuberculous mycobacteria (NTM) by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Adaptation of differential ion mobility spectrometry (DMS) for discrimination of specific biomarkers in exhaled breath in patients with severe renal-pulmonary dysfunction Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011 Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach Source: Eur Respir J 2003; 21: 414-420 Year: 2003